RayzeBio, Inc. Common Stock
NASDAQ: RYZB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kenneth Song
- Employees
- 88
- Headquarters
- United States
- IPO year
- 2023
- Market cap
- $3.8B
Loading RYZB…
Loading profile data…Frequently asked questions about RYZB
What does RayzeBio, Inc. Common Stock (RYZB) do?
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct...
Where does RYZB trade?
RayzeBio, Inc. Common Stock (RYZB) trades on the NASDAQ.
What sector is RYZB in?
RayzeBio, Inc. Common Stock (RYZB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of RayzeBio, Inc. Common Stock?
Kenneth Song is the chief executive officer of RayzeBio, Inc. Common Stock (RYZB).
Where is RayzeBio, Inc. Common Stock headquartered?
RayzeBio, Inc. Common Stock is headquartered in United States.
Does RYZB pay a dividend?
RayzeBio, Inc. Common Stock (RYZB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RYZB go public?
RayzeBio, Inc. Common Stock (RYZB) completed its initial public offering in 2023.